Vanda Pharmaceuticals Inc VNDA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
FDA Rejects Vanda Pharma's Application for Gastroparesis Drug Tradipitant
-
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis
-
FDA Decision Due on Vanda Pharma's Gastroparesis Drug
-
Vanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference
-
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
-
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
-
Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
-
Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
Trading Information
- Previous Close Price
- $4.54
- Day Range
- $4.49–4.61
- 52-Week Range
- $3.30–6.75
- Bid/Ask
- $4.52 / $4.69
- Market Cap
- $267.55 Mil
- Volume/Avg
- 3,251 / 613,488
Key Statistics
- Price/Earnings (Normalized)
- 58.32
- Price/Sales
- 1.46
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 203
- Website
- https://www.vandapharma.com
Comparables
Valuation
|
Metric
|
VNDA
|
CRMD
|
CPRX
|
|---|---|---|---|
Price/Earnings (Normalized) | 58.32 | — | 36.15 |
Price/Book Value | 0.49 | 9.90 | 3.89 |
Price/Sales | 1.46 | 588.03 | 5.47 |
Price/Cash Flow | — | — | 12.33 |
Price/Earnings
VNDA
CRMD
CPRX
Financial Strength
|
Metric
|
VNDA
|
CRMD
|
CPRX
|
|---|---|---|---|
Quick Ratio | 4.58 | 4.12 | 4.69 |
Current Ratio | 4.68 | 4.79 | 5.14 |
Interest Coverage | — | −1,599.40 | — |
Quick Ratio
VNDA
CRMD
CPRX
Profitability
|
Metric
|
VNDA
|
CRMD
|
CPRX
|
|---|---|---|---|
Return on Assets (Normalized) | 0.15% | −66.44% | 43.35% |
Return on Equity (Normalized) | 0.18% | −77.20% | 50.92% |
Return on Invested Capital (Normalized) | 0.17% | −81.35% | 50.52% |
Return on Assets
VNDA
CRMD
CPRX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Xzlbmfqvj | Llf | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gwgmrwmn | Nnnnws | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vbljqyxz | Kqlvg | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vflgqqq | Skhknbn | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Ncsyjgp | Txr | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Lvxzpylq | Rdjy | $28.3 Bil | |||
| Moderna Inc
MRNA
| Tkbbzspp | Qrkv | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Yvrjrxb | Xgdc | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qddwhll | Llsmjlr | $13.3 Bil | |||
| Incyte Corp
INCY
| Zdpwwvmx | Cqvkhwx | $13.0 Bil |
United States